Actively Recruiting
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Led by M.D. Anderson Cancer Center · Updated on 2025-11-13
1000
Participants Needed
10
Research Sites
318 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
CONDITIONS
Official Title
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histological or cytological confirmation of colorectal adenocarcinoma
- Patients with any stage of colorectal adenocarcinoma eligible for curative intent treatment
- Patients with stage II-IV colorectal cancer post-R0 resection enrolled before or up to 3 months after surgery and before starting adjuvant therapy
- Ability to understand and willing to sign informed consent
- Willingness to undergo standard surveillance after completing curative therapies
- Willingness to provide blood samples for research
You will not qualify if you...
- Presence of active cancers other than colorectal adenocarcinoma that could interfere with plasma marker detection or interpretation
- Severe systemic illnesses or concurrent diseases that would make participation inappropriate according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
Banner - MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
Terminated
2
Baptist- MD Anderson Cancer Center
Jacksonville, Florida, United States, 32207
Terminated
3
The Queen's Medical Center
Honolulu, Hawaii, United States, 96813
Terminated
4
St. Luke's Cancer Institute
Boise, Idaho, United States, 83712
Terminated
5
Cooper Hospital UNIV MED CTR.
Camden, New Jersey, United States, 08103
Terminated
6
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States, 75390
Terminated
7
Houston Methodist Cancer Center
Houston, Texas, United States, 77030
Terminated
8
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
9
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas, United States, 78229
Terminated
10
Baylor Scott & White Research Institute
Temple, Texas, United States, 76508
Terminated
Research Team
A
Arvind Dasari
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here